OXIS International,
Inc.
is engaged in the research, development and sale of products
that
counteract
the harmful effects of “oxidative stress.”
Oxidative
stress
refers to the situations in which the body’s antioxidant and other
defensive
abilities to combat free radicals (a.k.a highly reactive
species
of
oxygen and nitrogen) are overwhelmed and one’s normal
healthy
balance is either lost or severely compromised.
There products include therapeutic nutraceutical
products,
cosmeceutical
products and proprietary formulations and
clinical
products that are developed internally and/or out-licensed to
biotech
and pharmaceutical
companies as drug candidates.
Inc.
is engaged in the research, development and sale of products
that
counteract
the harmful effects of “oxidative stress.”
Oxidative
stress
refers to the situations in which the body’s antioxidant and other
defensive
abilities to combat free radicals (a.k.a highly reactive
species
of
oxygen and nitrogen) are overwhelmed and one’s normal
healthy
balance is either lost or severely compromised.
There products include therapeutic nutraceutical
products,
cosmeceutical
products and proprietary formulations and
clinical
products that are developed internally and/or out-licensed to
biotech
and pharmaceutical
companies as drug candidates.
They focus on
naturally occurring protective
substances
since they are more likely
to be both safe and
efficacious. Our
primary products incorporate
and emphasize the
multifaceted
“super antioxidant” compound,L-Ergothioneine (“ERGO”), as a
key
component. We own several patents and
pending applications
related
to ERGO that cover current and planned products
relevant to
our
nutraceutical and cosmecuetical businesses. Our patents and patent
applications
address ERGO’s protective effects and activities
and
the ERGO
manufacturing process.
No comments:
Post a Comment